MedTrace Logo

Natreon Healthy Skin Study - PrimaVie Supplement

NCT02762032 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-07-24

No results posted yet for this study

Summary

This study will demonstrate the ability of the oral supplement, PrimaVie® to improve skin microperfusion, hydration, elasticity and barrier function. 45 females will be enrolled in 1 of 3 arms where they will receive either 125 mg PrimaVie, 250 mg PrimaVie or placebo (control) to take twice daily for 14 weeks.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

PrimaVie Herbal Supplement 125

125 mg to take BID for 14 weeks in Arm 1

DIETARY_SUPPLEMENT

PrimaVie Herbal Supplement 250

250 mg to take BID for 14 weeks in Arm 2

DRUG

Placebo

Placebo supplement to take BID for 14 weeks in Arm 3

Sponsors & Collaborators

  • Natreon, Inc.

    collaborator INDUSTRY

  • Ohio State University

    lead OTHER

Principal Investigators

  • Gayle M Gordillo, M.D. · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02762032 on ClinicalTrials.gov